Papadimitrakopoulou V, et al. IMPOWER132: PFS and safety results with 1L atezolimumab + carboplatin/cisplatin + pemetrexed in stage IV non-squamous NSCLC. IASLC 2018; abstract OA05.07.
Eerste studie naar neoadjuvante immuuntherapie bij PCC van start
apr 2021 | Dermato-oncologie, Immuuntherapie